CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING
3.4. PATENTS ANALYSIS

3.4.1. Patent analysis by year
3.4.2. Patent analysis by region

3.5. PORTERS FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS

4.1. OVERVIEW

4.1.1. Market size & forecast

4.2. ADCETRIS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size & forecast

4.3. KADCYLA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size & forecast

CHAPTER 5 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION

5.1. OVERVIEW

5.1.1. Market size & forecast

5.2. CD30 ANTIBODIES

5.2.1. Market size & forecast

5.3. HER2 ANTIBODIES

5.3.1. Market size & forecast

CHAPTER 6 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION

6.1. OVERVIEW

6.1.1. Market size & forecast

6.2. BREAST CANCER

6.2.1. Market size & forecast

6.3. LYMPHOMA

6.3.1. Market size & forecast

CHAPTER 7 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY GEOGRAPHY

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size & forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size & forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.5. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size & forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.5. Taiwan market size and forecast
7.4.3.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size & forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. PFIZER, INC.

8.1.1. Operating business segments
8.1.2. Business performance

8.2. CELLDEX THERAPEUTICS INC.

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. SEATTLE GENETICS INC.

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. GENENTECH INC.

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. IMMUNOGEN INC.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.5. SANOFI S.A.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.7. IMMUNOMEDICS, INC.

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. PROGENICS PHARMACEUTICALS INC.

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.8. BAYER HEALTHCARE PHARMACEUTICALS

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.10. SYNTHON HOLDING B.V.

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments